Buy Advocate For Dogs Online
When applied as directed, Advocate spot-on prevents heartworm, and controls flea infestations, ear mites,roundworms and hookworms. It also treats whipworms, lice and sarcoptic mange in dogs, and treats lungworms in cats.
buy advocate for dogs online
Advocate spot on is available in both canine and feline formulas. Advocate may be used on dogs and puppies from 7 weeks, weighing at least 2.2 pounds (1 kg). It may be used on cats and kittens from 9 weeks, weighing at least 2.2 pounds (1 kg).
Advocate Spot-On Solution for Dogs is indicated for the treatment of dogs that are at risk from, or already suffering from mixed parasitic infections. It is particularly effective against flea infestations and their larvae, roundworms, hookworms, whipworms, ear mites, Demodex mites, and sarcoptic mange. It can also be effective in preventing heartworm disease.
Dosage and Administration The recommended minimum doses for cats are 10 mg/kg body weight imidacloprid and 1.0 mg/kg body weight moxidectin, equivalent to 0.1ml/kg body weight Advocate for cats. Dosage schedule for ferrets: one pipette of Advocate spot-on solution for small cats and ferrets (0.4 ml) should be administered per animal. Do not exceed the recommended dose. The recommended minimum doses for dogs are 10 mg/kg body weight imidacloprid and 2.5 mg/kg body weight moxidectin, equivalent to 0.1ml/kg body weight Advocate for dogs. The treatment schedule for all species should be based on individual veterinary diagnosis and on the local epidemiological situation.
Treatment of Ear Mite Infestation (Otodectes cynotis) A single dose of the product should be administered. In dogs, loose debris should be gently removed from the external ear canal at each treatment. For both cats and dogs, a further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment. Do not apply directly to the ear canal.
Treatment of Demodicosis (caused by Demodex canis) The administration of a single dose every 4 weeks for 2 to 4 months is efficacious against Demodex canis and leads to a marked improvement of clinical signs particularly in mild to moderate cases. Especially severe cases may require more prolonged and more frequent treatment. To achieve the best possible response in these severe cases, at the discretion of the veterinarian, Advocate can be applied once a week and for a prolonged time. In all cases it is essential that the treatment should be continued until skin scrapings are negative on at least 2 consecutive monthly occasions. Treatment should be stopped in dogs that show no improvement or do not respond in mite count after 2 months treatment. Alternative treatment should be administered. Seek the advice of your veterinarian. As demodicosis is a multi-factorial disease, where possible, it is advisable to also treat any underlying disease appropriately.
Roundworm, Hookworm and Whipworm Treatment (Toxocara Canis, Ancylostoma Caninum, Uncinaria Stenocephala, Toxascaris Leonina and Trichuris Vulpis) In areas endemic for heartworm, monthly treatment may significantly reduce the risk of re-infection caused by the respective round-, hook- and whipworms. In areas non-endemic for heartworm, the product can be used as part of a seasonal prevention programme against fleas and gastrointestinal nematodes. Studies have shown that monthly treatment of dogs will prevent infections caused by Uncinaria stenocephala.
Contra-Indications, Warnings, etc Do not use in puppies under 7 weeks of age. Treatment of dogs weighing less than 1 kg should be based on a risk-benefit assessment. Do not use in the cases of hypersensitivity to the active substances or to any of the excipients. There is limited experience on the use of the product in sick and debilitated animals, thus the product should only be used based on a risk-benefit assessment for these animals. For dogs, the corresponding "Advocate for dog" product, which contains 100 mg/ml imidacloprid and 25 mg/ml moxidectin, must be used. Do not use on canaries. Do not apply in the mouth, in the eyes or the ears of the animal. Care should be taken that the product is not ingested by animals and does not come into contact with the eyes or mouth of the recipient and/or other animals. Consider carefully the correct application method described in the 'Method of Application' section, especially that the product should be applied to the site specified in order to minimise the risk for the animal to lick the product. Do not allow recently treated animals to groom each other. Do not allow treated animals to come into contact with untreated animals until the application site is dry. When the product is applied in 3 to 4 separate spots (see the 'Method of Application' section), specific care should be taken to prevent the animal licking the application sites. During treatment with Advocate no other antiparasitic macrocyclic lactone should be administered. This product contains moxidectin (a macrocyclic lactone), therefore special care should be taken with Collie or Old English Sheep dogs and related breeds or crossbreeds, to correctly administer the product as described under the 'Method of Application' section; in particular, oral uptake by Collie or Old English Sheep dogs and related breeds or crossbreeds should be prevented. The product tastes bitter. Salivation may occasionally occur if the animal licks the application site immediately after treatment. This is not a sign of intoxication and disappears within some minutes without treatment. Correct application will minimise licking of the application site. In case of accidental oral uptake, symptomatic treatment should be administered. There is no known specific antidote. The use of activated charcoal may be beneficial. After accidental oral ingestion (e.g. licking at the site of application) or overdose, neurological signs (most of which are transient) such as ataxia, generalised tremors, ocular signs (dilated pupils, little pupillary reflex, nystagmus), abnormal respiration, salivation and vomiting may be observed in very rare cases. The use of the product may result in transient pruritus in the animal. Vomiting can occur on rare occasions. In dogs transient local skin sensitivity reactions including increased itching, hair loss, greasy fur and redness at application site have been reported in very rare cases in spontaneous (pharmacovigilance) reports. If the animal licks the application site after treatment, neurological signs (most of which are transient) may be observed in very rare cases (see below). The product may, in rare cases cause local hypersensitivity reactions. The product may in very rare cases cause at the application site a sensation resulting in transient behavioural changes such as lethargy, agitation, and inappetence.
Ivermectin-sensitive Collie dogs tolerated up to 5 times the recommended dose repeated at monthly intervals without any adverse effects, but the safety of application at weekly intervals has not been investigated in ivermectin-sensitive Collie dogs. When 40% of the unit dose was given orally, severe neurological signs were observed. Oral administration of 10% of the recommended dose produced no adverse effects. Up to 10 times the recommended dose was tolerated in adult dogs with no evidence of adverse effects or undesirable clinical signs. Five times the recommended minimum dose applied at weekly intervals for 17 weeks was investigated in dogs aged over 6 months and tolerated with no evidence of adverse effects or undesirable clinical signs. The product was administered to puppies at up to 5 times the recommended dose, every 2 weeks for 6 treatments, and there were no serious safety concerns. Transient mydriasis, salivation, vomiting and transient rapid respiration were observed. Although experimental overdosage studies have shown that the product may be safely administered to dogs infected with adult heartworms, it has no therapeutic effect against adult Dirofilaria immitis. It is therefore recommended that all dogs 6 months of age or more, living in areas endemic for heartworm, should be tested for existing adult heartworm infection before being treated with the product. At the discretion of the veterinarian, infected dogs should be treated with an adulticide to remove adult heartworms. The safety of Advocate has not been evaluated when administered on the same day as an adulticide. Dogs infected with adult heartworms tolerated up to 5 times the recommended dose, every 2 weeks for 3 treatments, without any adverse effects. The safety of the product has only been evaluated in dogs classified as either Class 1 or 2 for heartworm disease in laboratory studies and in a few Class 3 dogs in a field study. Therefore the use in dogs with obvious or severe symptoms of the disease should be based on a careful benefit risk assessment by the treating veterinarian. Do not use in dogs classified as Class 4 for heartworm disease as the safety of the product has not been evaluated in this animal group. A field study has shown that in heartworm positive dogs with microfilaremia there is a risk of severe respiratory signs (coughing, tachypnoea and dyspnoea) that may require prompt veterinary treatment. In the study these reactions were common (seen in 2 of 106 treated dogs). Gastrointestinal signs (vomiting, diarrhoea, inappetence) and lethargy are also common adverse reactions following treatment in such dogs. Efficacy against adult Dirofilaria repens has not been tested under field conditions. Imidacloprid is toxic for birds, especially canaries. No interactions between Advocate and routinely used veterinary medicinal products or medical or surgical procedures have been observed. Safety of Advocate when administered on the same day as an adulticide to remove adult heartworms has not been evaluated. Brief contact of the animal with water on one or two occasions between monthly treatments is unlikely to significantly reduce the efficacy of the product. However, frequent shampooing or immersion of the animal in water after treatment may reduce the efficacy of the product. Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class. Therefore, the use of this product should be based on the assessment of each individual case and on local epidemiological information about the current susceptibility of the target species in order to limit the possibility of a future selection for resistance. The use of the product should be based on the confirmed diagnosis of mixed infection (or risk of infection, where prevention applies) at the same time. 041b061a72